Sponsored by
The phase 2/3 GBM AGILE platform trial has now reported final results for the regorafenib (Stivarga) arm. In the study, regorafenib was tested in both recurrent glioblastoma (against lomustine) and newly diagnosed unmethylated glioblastoma (against standard chemoradiation). The trial did not find an overall survival benefit in either group, and regorafenib was associated with more toxicity compared to control. These findings are not entirely surprising given the modest survival signal seen in the earlier phase 2 REGOMA trial for recurrent GBM.
While disappointing, the GBM AGILE platform continues to represent an important advance in GBM drug development by enabling rapid, randomized testing of drug candidates within an adaptive framework, allowing ineffective agents to be deprioritized more efficiently.
From a broader perspective, these results also reinforce a recurring theme in GBM: monotherapy approaches, particularly with targeted kinase inhibitors, have repeatedly failed to translate early-phase signals into durable clinical benefit. This underscores the need for rational combination strategies that address the multiple redundant resistance pathways that drive GBM progression.